|
Dec 28 2021
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 07 2021
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update
|
|
Dec 01 2021
Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit
|
|
Nov 12 2021
Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update
|
|
Nov 11 2021
Gain Therapeutics Presents Parkinson’s Disease Preclinical Study Results at Society for Neuroscience Annual Meeting
|
|
Nov 10 2021
Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinson’s Disease and Gaucher Disease
|
|
Nov 04 2021
Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
|
|
Oct 28 2021
Gain Therapeutics to Present at Upcoming Medical Conferences
|
|
Oct 26 2021
Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)
|
|
Oct 19 2021
Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer
|
|
Sep 23 2021
Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
|
|
Sep 17 2021
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
|
|
Sep 09 2021
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
|
|
Sep 08 2021
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
|
|
Sep 02 2021
Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
|
|
Aug 11 2021
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
|
|
Aug 03 2021
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
|
|
Jun 10 2021
Gain Therapeutics Announces Issuance Of Two New Pct Patents Covering Gba And Galc Modulator Compounds For Treatment Of Cns Disorders
|
|
May 27 2021
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
|
|
May 17 2021
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
|
|
May 10 2021
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
|
|
May 03 2021
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
|
|
Apr 27 2021
Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
|
|
Apr 22 2021
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress
|
|
Apr 20 2021
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
|
|
Mar 25 2021
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
|
|
Mar 18 2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
|
|
Mar 10 2021
Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering
|
|
Feb 11 2021
Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B Programs at the 17th Annual WORLDSymposium™
|
|
Feb 04 2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
|
|
Feb 02 2021
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
|
